Vitrolife Group (VITR) Pre-close call presentation summary

Key financial and operational highlights

• Technologies product group achieved 40% organic sales growth in Q2 2024, with a strong EBITDA margin driven by this performance.

• Americas and EMEA regions saw significant sales growth, while APAC growth remained modest at 2%.

• Currency headwinds impacted results in H1 2025 due to SEK strength, affecting both translation and transaction exposures.

• Tariffs on medical devices remain a challenge, especially in the US and China, prompting price increases and supply chain adjustments.

• Activities in certain markets discontinued from January 2025 due to international sanctions, affecting less than 3% of annual revenue.

Market and regulatory environment

• US IVF cycles declined in Q2 2025, partly as couples postponed treatment in anticipation of policy changes from the IVF Executive Order.

• High out-of-pocket costs and consumer confidence issues continue to impact IVF demand in the US.

• APAC region shows only small signs of cycle recovery, with overall IVF cycles below global averages due to high child-rearing costs and shifting reimbursement policies in China.

• No significant uplift in APAC cycles despite changes in Chinese reimbursement and care site policies.

Legal and compliance updates

• Officially served with a complaint regarding PGT-A genetic testing in the US as of May 15, 2025; defense preparations are ongoing.

• PGT-A testing requires both physician requisition and patient consent, ensuring compliance with clinical protocols.

• Ongoing risk assessment led to market exits to maintain compliance with international sanctions.